Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

GlobeNewswire October 2, 2019

Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 30, 2019

Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

GlobeNewswire September 4, 2019

Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire September 3, 2019

Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results

GlobeNewswire August 1, 2019

Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas

GlobeNewswire June 2, 2019

Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 15, 2019

Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301

GlobeNewswire May 15, 2019

Aduro Biotech Reports First Quarter 2019 Financial Results

GlobeNewswire May 7, 2019

Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors

GlobeNewswire April 18, 2019

Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting

GlobeNewswire April 17, 2019

Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire April 1, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Benzinga.com  March 30, 2019

Aduro Biotech to Present at Two Upcoming Investor Conferences in March

GlobeNewswire March 7, 2019

Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019

GlobeNewswire February 28, 2019

Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire February 27, 2019

Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 21, 2019

Aduro Announces Changes to its Board of Directors

GlobeNewswire February 21, 2019

Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications

GlobeNewswire February 14, 2019

Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma

GlobeNewswire February 11, 2019